The intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: In situ rat intestinal perfusion studies

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1574-1581

  Eriksson, André H ^a,c   Varma, Manthena V S ^a,d   Perkins, Everett J ^b   Zimmerman, Cheryl L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Active transport; Gly Sar; In situ intestinal perfusion; Intestinal absorption; LY354740; LY544344; Membrane transport transporters; PEPT1; Peptide transporters; Prodrugs

Indexed keywords

EGLUMETAD; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; PEPTIDE TRANSPORTER 1; PRODRUG; TALAGLUMETAD;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE PERFUSION; MALE; MEMBRANE TRANSPORT; NONHUMAN; RAT;

EID: 76649126188     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21917     Document Type: Article

References (24)

1. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. 1998. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660.
2. Vandergriff J, Rasmussen K. 1999. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 38:217-222.
3. Cartmell J, Monn JA, Schoepp DD. 1999. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170.
4. Johnson JT, Mattiuz EL, Chay SH, Herman JL, Wheeler WJ, Kassahun K, Swanson SP, Philips DL. 2002. The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. Drug Metab Dispos 30:27-33.
5. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
6. Leibach FH, Ganapathy V. 1996. Peptide transporters in the intestine and the kidney. Annu Rev Nutr 16:99-119.
7. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. 2000. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 89: 781-789.
8. +/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 16:55-61.
9. Sinko PJ, Balimane PV. 1998. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 19:209-217.
10. Bueno AB, Collado I, de Dios A, Dominguez C, Martin JA, Martin LM, Martinez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA, Herin MF. 2005. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J Med Chem 48:5305-5320.
11. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, McKinzie DL. 2006. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: In vivo pharmacology of LY544344. J Pharmacol Exp Ther 316:905-913.
12. Perkins EJ, Abraham T. 2007. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S, 2S,5R,6S)-2-[(2'S)-(2-Amino)propionyl]aminobicyclo[ 3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: Assessment of first-pass bioactivation and dose linearity. Drug Metab Dispos 35:1903-1909.
13. Lennernas H. 1998. Human intestinal permeability. J Pharm Sci 87:403-410.
14. Amidon GE, Ho NFH, French AB, Higuchi WI. 1981. Predicted absorption rates with simultaneous bulk fluid flow in the intestinal tract. J Theor Biol 89:195-210.
15. Soria I, Zimmerman CL. 1994. Intestinal absorption of (-)carbovir in the rat. Pharm Res 11:267-271.
16. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Contr AC-19:716-723.
17. Herrera-Ruiz D, Knipp GT. 2003. Current perspectives on established and putative mammalian oligopeptide transporters. J Pharm Sci 92:691-714.
18. Varma MVS, Eriksson AH, Sawada G, Pak YA, Perkins EJ, Zimmerman CL. 2009. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl] aminobicyclo[3.1.0]hexane-2, 6-dicarboxylate (LY544344). Drug Metab Dispos 37:211-220.
19. +/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 220:848-852.
20. Naruhashi K, Sai Y, Tamai I, Suzuki N, Tsuji A. 2002. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm Res 19:1417-1423.
21. Steel A, Nussberger S, Romero MF, Boron WF, Boyd CAR, Hediger MA. 1997. Stoichiometry and pH dependence of the rabbit proton-dependent oligopeptide transporter PepT1. J Physiol 498.3: 563-569.
22. Yang CY, Dantzig AH, Pidgeon C. 1999. Intestinal peptide transport systems and oral drug bioavailability. Pharm Res 16:1331-1343.
23. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K. 2005. Effects of a metabotropic glutamate(2/3) receptor agonist (LY 544344/ LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: Preliminary results. Psychopharmacology (Berl) 179: 310-315.
24. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. 2008. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33:1603-1610.